MedTrace Logo

Arginase Inhibition in Humans With Obesity

NCT05536934 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2022-09-13

No results posted yet for this study

Summary

To evaluate the efficacy of arginase inhibition on endothelial function in humans with obesity.

Conditions

  • Obese
  • Endothelial Function

Interventions

DRUG

Nω-hydroxy-nor-arginine

Sponsors & Collaborators

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-31
Primary Completion
2021-09-30
Completion
2022-03-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05536934 on ClinicalTrials.gov